← Back to headlines
ImmunityBio Acquires U.S. Rights to Tokyo Strain of BCG
ImmunityBio has announced its acquisition of the U.S. rights to the Tokyo strain of Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis and also for bladder cancer treatment.
16 May, 18:11 — 16 May, 18:11
Sources
Showing 1 of 1 sources
Related Stories
Irish Health Agency Fined €645,000 for Storing Records in Derelict Sites
1h ago
New Urine Test Detects Over 90 Percent of Bladder Cancer Cases
2h ago
Swimmer Hospitalized Following Suspected Shark Attack in Massachusetts
5h ago
Wellington Clinics Suspends Kidney Transplants Amid Organ Harvesting Probe
11h ago